Targeted accurate RNA consensus sequencing (tARC-seq) reveals mechanisms of replication error affecting SARS-CoV-2 divergence.
Catherine C BradleyChen WangAlasdair J E GordonAlice X WenPamela N LunaMatthew B CookeBrendan F KohrnScott R KennedyVasanthi AvadhanulaPedro A PiedraOlivier LichtargeChad A ShawShannon E RoncaChristophe HermanPublished in: Nature microbiology (2024)
RNA viruses, like SARS-CoV-2, depend on their RNA-dependent RNA polymerases (RdRp) for replication, which is error prone. Monitoring replication errors is crucial for understanding the virus's evolution. Current methods lack the precision to detect rare de novo RNA mutations, particularly in low-input samples such as those from patients. Here we introduce a targeted accurate RNA consensus sequencing method (tARC-seq) to accurately determine the mutation frequency and types in SARS-CoV-2, both in cell culture and clinical samples. Our findings show an average of 2.68 × 10 -5 de novo errors per cycle with a C > T bias that cannot be solely attributed to APOBEC editing. We identified hotspots and cold spots throughout the genome, correlating with high or low GC content, and pinpointed transcription regulatory sites as regions more susceptible to errors. tARC-seq captured template switching events including insertions, deletions and complex mutations. These insights shed light on the genetic diversity generation and evolutionary dynamics of SARS-CoV-2.
Keyphrases
- sars cov
- single cell
- genome wide
- respiratory syndrome coronavirus
- genetic diversity
- rna seq
- end stage renal disease
- transcription factor
- cancer therapy
- crispr cas
- patient safety
- emergency department
- ejection fraction
- high resolution
- newly diagnosed
- chronic kidney disease
- drug delivery
- adverse drug
- clinical practice
- prognostic factors
- gas chromatography
- simultaneous determination
- high throughput sequencing